Oriana has global experience creating and leading teams and organizations resulting in successful strategic exits. She brings a wealth of knowledge and expertise from women's health startups and large life science companies, and a passion for entrepreneurship and solving problems that disproportionality affect women. Recognized for her inspirational leadership, Oriana is known for developing a highly productive culture and turning visions into reality.
Alongside her leadership qualities, Oriana has a proven technical record of creating market entry strategies and product launches in new markets alongside driving market share growth in existing diagnostic assay and instrument markets.
Oriana is responsible for building and leading the AOA team, fundraising and developing and executing long-term strategies.
Oriana holds a degree from Boston University in Economics and International Relations, and she has experience both living and working in various geographies.
CEO & Co-Founder
Alex is a passionate and dedicated business leader with a track record of launching UK medical device and diagnostics sales companies. He has extensive experience priming markets, launching products and driving early product sales.
In most recent roles, Alex has been committed to commercializing and launching innovative, disruptive products through his own businesses across European healthcare markets with a primary focus on obstetrics and gynecology.
Alex works closely with Oriana, ensuring strategies relating to finance, accounting, legal and fundraising are executed in a timely manner. On a daily basis, Alex ensures AOA's operations are running smoothly and efficiently.
Alex has a degree and MSc from the University of Southampton and University College London.
COO & Co-Founder
Anna is a dynamic business leader with a passion for advancing healthcare through world-class diagnostics.
Most recently Anna led multiple business development teams for companies focused on novel diagnostic devices including maternal fetal medicine and inflammatory autoimmune diseases, encompassing product development, clinical development, economic modeling, marketing and launch.
Anna has overseen the inclusion of multiple product into national and pan-European guidelines, and she has experience with US FDA submissions for 510(k), PMA, and CLIA LTD regulatory routes.
As Chief Development Officer, Anna has overall responsibility for fulfilling AOA's scientific mission, product development and building shareholder value.
Anna holds a degree in International Finance and Business Administration from Boston University Questrom School of Management.
CDO & Co-Founder
Prasad is a visionary leader and a technical expert. He is a proven executive with a successful track record of translating several bench top technologies into validated biomarker panels for regulatory submissions - LDT, 510k, PMA - in oncology, neurology, hematology, and clinical chemistry domain. More recently, as an R&D Director and PI, Prasad led the successful FDA PMA submission for a novel prostate cancer diagnostic test, which also received Breakthrough Device Designation in 2019.
As a Vice President for R&D, Prasad is responsible for AOA’s product lifecycle from research to commercialization, currently leading the development, validation, and eventual FDA submission for the ovarian cancer diagnostic test. Prasad works on developing proprietary technology for monoclonal antibodies and immunoassays development for various diagnostic and therapeutic targets, system integration and IP analysis.
Prasad has completed B.Tech. in Chemical Engineering from ICT Mumbai and Ph.D. in Biological Chemistry-Biotechnology from University of California-Davis USA. Prasad has worked in world renowned global organizations, such as Fred Hutchinson Cancer Research Center, UC Davis Medical Center, Genentech, Novartis, National Chemical Laboratory-India, and IIT Bombay-India.
Prasad Gawande PhD
Vice President R&D
Elizabeth is a clinical research professional specializing in the management of clinical operations, quality, and regulatory oversight of global clinical trials in multiple therapeutic areas in biopharmaceutical, medical device and diagnostics.
Elizabeth has extensive experience in all phases of clinical trials that allowed market access for strategic business initiatives. She is Project Management certified through PMI and has been involved in the clinical trial process from development to regulatory approval applying a strong focus on risk and quality oversight.
As Director of Clinical Operations, Elizabeth has overall responsibility for leading AOA's clinical trial operations.
Elizabeth holds an undergraduate degree in Organizational Leadership and a MSc. in Health Outcomes Research from St. Louis University.
Director of Clinical Operations
Andrea is a passionate leader who excels at scaling up systems and solutions to create positive outcomes for community stakeholders.
Having graduated from the Boston University Questrom School of Management with a degree in Marketing, she was a 2009 Teach for America Corps member, serving in Chelsea MA.
After spending 13 years working in charter and turnaround schools as a school leader she has pivoted to ensuring behind the scenes operations at AOA Dx run smoothly in order to accomplish our mission critical goals.
While she has worked for AOA part time since 2020, she is excited to support the team full time in finance, HR, marketing, and project management.
Director of Business Operations
Dr. Saragovi is a passionate and world-leading scientist in the area of Translational Medicine.
Dr. Saragovi has published over 200 publications and 21 patents, primarily focusing translational medicine. More recently Dr. Saragovi has focused on the targeting of gangliosides, which are used clinically for cancer diagnosis, prognosis, and therapy.
Dr. Saragovi based at McGill University and Lady Davis Institute at the Jewish General Hospital, Montreal.
Professor Uri Saragovi, PhD
Chief Scientific Officer
Surbhi Sarna is the founder and former CEO of nVision medical, a medical device company that, to date, is the only device cleared by the FDA to collect cells from the fallopian tube for the detection of ovarian cancer. Having led the company from inception, nVision Medical was acquired by Boston Scientific in 2018 for $275m.
Most recently Surbhi became Y Combinator’s first-ever partner for healthcare and biotech, and she currently sits on the board of Penumbra, Progenity, Astia, Draper University and the Harker School. Surbhi has extensive experience with early product development, funding, clinical trials and commercialization.
Independent Board Member
Elizabeth Garner, MD, MPH has over a decade of pharmaceutical development experience. She also has deep expertise in clinical trial design and execution. She has held roles of increasing strategic responsibility in large and small companies, including ObsEva SA, Merck, Abbott (AbbVie), Myriad Genetics, and Agile Therapeutics. In addition to Pharm-Olam, she is also on the Boards of the Drug Information Association (DIA) and the American Medical Women’s Association (AMWA), and she was a 2019 awardee of the PharmaVoice 100 most inspiring individuals in the life-sciences industry.
Dr. Garner is currently the Chief Scientific Officer at Ferring Pharmaceuticals, a biopharmaceutical company that focuses on the development of innovative products in the areas of reproductive medicine and maternal health, urology and gastroenterology. Dr. Garner received joint MD and MPH degrees from Harvard Medical School and the Harvard School of Public Health. She was trained in obstetrics and gynecology at Brigham and Women’s/Massachusetts General Hospitals and completed a fellowship in gynecologic oncology at Brigham and Women’s and Dana Farber Cancer Institute.
Awards and Accelerators